top of page
Green-DNA.png

Primary Product

NKA01 - A novel drug to prolong life after injury & blood loss

Future Users

Military Medics, Ambulances, Hospitals, Surgeons, Strategic Stockpiles

Stage & Sector

Early-Stage Biotech w/ Proof of Concept in Small Animal Studies

Our Focus

Lead Optimization of NKA01, an antibody designed to neutralize the Shock Toxin

About Us

Mission: NKA Bio was founded with a mission to improve trauma care by solving shock. The company is focused on its primary product NKA01 for Trauma Resuscitation. The early-stage pipeline in development includes programs for septic shock, acute lung injury, and heart attack resuscitation.

What is Shock?

The Definition

Our body’s stress response to blood loss (hemorrhage).

The Causes

Car Crashes, Gun Shot Wounds, Burns, & Combat Injuries

The Symptoms

Low blood pressure & high potassium; commonly fatal.

The Impact

Injury is the #1 Cause of Death People Ages 1 - 44 in the United States

Future

NKABio_Blue-Thin.png

We Believe in a Better Future for Patients in Shock

NKA Bio Believes in a Future Where...

You are administered NKA01 at the scene of injury to allow for more time to get to a hospital before shock kills you.

NKA01 keeps you alive long enough for trauma teams to stop the bleeding and repair your injuries.

You can survive shock, giving you the opportunity to recover from an otherwise fatal injury & return home to your family.

Market

Every day, medical professionals in the US run out of time and patients bleed to death. On average:
  • 148,000 people die every year from hemorrhage-related injuries.

  • Annually, 211,530 hemorrhage-related patients admitted to trauma center ICUs.

  • In the US, most hemorrhage-related trauma patients spend 3-4 days in the ICU.

  • Reducing ICU care would save a per-patient average of $4,300 per day.

A drug to resuscitate and stabilize patients in shock, would create an opportunity to save lives and reduce trauma care costs.

Hemorrhagic Shock

4M

 

People Killed Globally by Trauma Associated with Injury & Violence

World Health Organization

Septic Shock

11M

 

People Killed Globally by Viral & Bacterial Infections Turned Septic

Rudd et al 2020

Cardiogenic Shock

14M

 

People Killed Globally by Cardiac Insults Including Heart Attacks and Strokes

World Health Organization

Circulatory Shock is a Global Problem

Pipeline

Intertwined
NKA Bio's Critical Care Pipeline
Product
Indication
Discovery
Lead
Optimization
Safety
Toxicology
Hemorrhagic
Shock
NKA01
Septic Shock
(Endotoxic)
NKA02
NKA03
Acute Lung Injury
& ARDS
NKA04
Heart Attack
Resuscitation
All IP is Owned by NKA Bio, and All Programs are Available for Licensing & Partnership

World Health Organization

Team

Grey Round Patterns
Gann Headshop Hopkins Surgery_edited.jpg

Shock Pioneer Behind Discovery 

(1932 - 2020)

Dr. Gann was a pioneer and leader in trauma care and biomedical engineering, serving as the first Director of Emergency Medicine at Johns Hopkins and the first Chair of Biomedical Engineering at Case Western Reserve. A polymath with a background in physics, philosophy, and medicine, Dr. Gann's research was continuously funded by the NIH to study the body's response to hemorrhage.

48927.png

Donald S.
Gann, MD

Susan
Gann Hibbs

Chief Executive Officer

Corporate Vision

Investor Relations

Corporate Operations

  • LinkedIn
74351762_2804088276281788_1017219491743924224_o_edited_edited.jpg

Lewis C.
Hibbs III

Chief Operating Officer

R&D Operations

Antibody Engineering

Research & Grant Writing

  • LinkedIn

Les E.
Johnson

Chief Technology Officer

Global Drug Development

Regulatory Lead

Quality & Risk Management

  • LinkedIn
74351762_2804088276281788_1017219491743924224_o_edited_edited.jpg

SUPPORT

Advisors

Military Medicine

John-Ingari.png

Trauma & Clinical Trials

MOORE_edited.png

Antibody Engineering

download.jpg
LBH-BIOINCUBATOR.png

Contacts

Accredited Investors

Or Send Us An Email

Liquid Bubbles
bottom of page